The prospect of a pill rather than an injection is obviously appealing to some people, but will fear of needles be enough to ...

Half of the participants took a semaglutide tablet daily and half took a placebo. Participants continued their assigned regimen for an average of just under four years. By the end of the trial ...

However, at the two-year, three-year, and four-year time points from the index date, those taking semaglutide had an increased risk for NAION (hazard ratios, 2.39, 2.44, and 2.05, respectively).

The large-scale study focused on use of semaglutide and non-GLP-1 RAs. An increased risk for nonarteritic anterior ischemic optic neuropathy with semaglutide was seen at 2, 3 and 4 years from the ...

Most common gastrointestinal issues seen were nausea/vomiting, abdominal pain, and diarrhea. HealthDay News — The rate of emergency department visits for adverse events among patients dispensed ...

Semaglutide use associated with increased risk for NAION at the two-, three-, and four-year time point from the index date. (HealthDay News) — For patients with diabetes, semaglutide use is ...

Semaglutide, the medication better known as Ozempic, reduces the symptoms of a condition that can lead to lower limb amputations in people with diabetes, according to a new study that reinforces ...

The researchers found that based on 551 cases, there were an estimated 24,499 emergency department visits attributed to semaglutide adverse events in 2022 through 2023 (mean patient age, 50.9 ...

The use of semaglutide in patients with diabetes was associated with a significantly increased risk for nonarteritic anterior ischemic optic neuropathy (NAION) compared with those taking drugs for ...